rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
16
|
pubmed:dateCreated |
1993-8-31
|
pubmed:abstractText |
A variety of human tumors frequently express high levels of epidermal growth factor (EGF) receptor and its ligand, transforming growth factor alpha (TGF-alpha), which in some tumors is associated with poor prognosis. Monoclonal antibodies (MAbs) that block the binding of TGF-alpha or EGF to the receptor can inhibit proliferation of tumor cells that express the receptor. Studies suggest that these MAbs may enhance the antitumor effects of chemotherapy.
|
pubmed:grant |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0027-8874
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
18
|
pubmed:volume |
85
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1327-33
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:8340945-Adenocarcinoma,
pubmed-meshheading:8340945-Animals,
pubmed-meshheading:8340945-Antibodies, Monoclonal,
pubmed-meshheading:8340945-Carcinoma, Squamous Cell,
pubmed-meshheading:8340945-Combined Modality Therapy,
pubmed-meshheading:8340945-Dose-Response Relationship, Drug,
pubmed-meshheading:8340945-Doxorubicin,
pubmed-meshheading:8340945-Humans,
pubmed-meshheading:8340945-Mice,
pubmed-meshheading:8340945-Mice, Inbred BALB C,
pubmed-meshheading:8340945-Mice, Nude,
pubmed-meshheading:8340945-Neoplasm Transplantation,
pubmed-meshheading:8340945-Receptor, Epidermal Growth Factor,
pubmed-meshheading:8340945-Tumor Cells, Cultured
|
pubmed:year |
1993
|
pubmed:articleTitle |
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
|
pubmed:affiliation |
Department of Medicine, Cornell University Medical College, New York, N.Y.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|